Journal of Psychiatric Research - The Consciousness Library

The neuroscience of spirituality, religion, and mental health: A systematic review and synthesis.

Journal of Psychiatric Research December 1, 2022 David H Rosmarin, Caroline C Kaufman, Stephanie Friree Ford et al.

Prior research highlights the importance of spirituality/religion (S/R) as it relates to several aspects of mental health and clinical interventions. This research has been expanded to include the concurrent examination of neurobiological correlates of S/R to elucidate potential biological mechanisms. However, the majority of neurobiological research on S/R has neglected mental health, and the...

DOI: 10.1016/j.jpsychires.2022.10.003 Full text Anxiety Depression Alcohol abuse Neurobiology +2

Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis.

Journal of Psychiatric Research May 1, 2022 Yazen Alnefeesi, David C J Chen-Li, Ella Krane et al. 177 citations

Ketamine is a promising therapeutic option in treatment-resistant depression (TRD). The acute efficacy of ketamine in TRD has been demonstrated in replicated randomised-controlled trials (RCTs), but the generalizability of RCT data to real-world practice is limited. To this end, we conducted a systematic review (Search date: 25/12/2021; 1482 records identified) and meta-analysis of studies...

DOI: 10.1016/j.jpsychires.2022.04.037

The abuse liability of ketamine: A scoping review of preclinical and clinical studies.

Journal of Psychiatric Research May 1, 2022 Tuyen T. Le, Isabel Pazos Cordero, Muhammad Youshay Jawad et al. 82 citations

While ketamine has been used clinically over the past decades, it has only been recently shown to be a promising therapy for treatment-resistant depression (TRD). However, ketamine and related dissociative agents may also be misused recreationally, creating significant concerns for abuse liability when prescribed for depression. Although the abuse potential of ketamine is widely recognized,...

DOI: 10.1016/j.jpsychires.2022.04.035

MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD.

Journal of Psychiatric Research May 1, 2022 Timothy D Brewerton, Julie B. Wang, Adele Lafrance et al. 81 citations

Eating disorders (EDs) and posttraumatic stress disorder (PTSD) are highly comorbid, yet there are no proven integrative treatment modalities for ED-PTSD. In clinical trials, MDMA-assisted therapy (MDMA-AT) has shown marked success in the treatment of PTSD and may be promising for ED-PTSD. Ninety individuals with severe PTSD received treatment in a double-blind, placebo-controlled pivotal trial...

DOI: 10.1016/j.jpsychires.2022.03.008 Full text Psychedelic-assisted therapy Eat-26 Eating disorders MDMA-Assisted Therapy +3

The resilient phenotype elicited by ketamine against inflammatory stressors-induced depressive-like behavior is associated with NLRP3-driven signaling pathway.

Journal of Psychiatric Research September 30, 2021 A. Camargo, A. P. Dalmagro, I. A. Wolin et al.

Ketamine has emerged as a prophylactic agent against depressive-like behavior induced by stress. However, the possible pro-resilience effects of ketamine against inflammatory stressors-induced depressive-like behavior and the signaling pathways associated with this response remain to be determined. Therefore, this study investigated the ability of prophylactic ketamine administration to produce...

DOI: 10.1016/j.jpsychires.2021.09.057

Registered clinical studies investigating psychedelic drugs for psychiatric disorders.

Journal of Psychiatric Research July 1, 2021 Ashley N. Siegel, Shakila Meshkat, Katie Benitah et al. 101 citations

Psychedelics are a hallucinogenic class of psychoactive drugs with the primary effect of activating non-ordinary states of consciousness. Due to the positive preliminary findings of these drugs in the treatment of psychiatric disorders, the number of registered clinical studies has risen significantly. In this paper, clinical studies registered on clinicaltrials.gov that evaluate the treatment...

DOI: 10.1016/j.jpsychires.2021.05.019 Full text Ayahuasca DMT Depression Ibogaine +9

Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial.

Journal of Psychiatric Research May 8, 2021 Rodrigo P Mello, Mariana V F Echegaray, A. P. Jesus-Nunes et al. 22 citations

Dissociative symptoms are common, possibly severe, side effects associated with the use of ketamine and esketamine in depression. We investigated the relationship between trait dissociation and dissociation induced by ketamine and esketamine used as augmentation therapy in treatment-resistant depression (TRD). Adults with TRD were randomly assigned to receive a single intravenous infusion, with...

DOI: 10.1016/j.jpsychires.2021.05.014

Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review.

Journal of Psychiatric Research May 1, 2021 Bruno Romeo, Marianne Hermand, Amélie Pétillion et al. 74 citations

The use of psychedelic treatments has shown very promising results in some psychiatric and addictive disorders, but not all patients achieved a response. The aim of this review is to explore the clinical and biological factors which could predict the response to psychedelics in psychiatric and addictive disorders. A systematic research was performed on MEDLINE, PsycInfo, Web of science, and...

DOI: 10.1016/j.jpsychires.2021.03.002 Full text Ayahuasca Psilocybin Addictive disorders Psychedelics +1

The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic review.

Journal of Psychiatric Research March 1, 2021 Joshua D. Di Vincenzo, Ashley N. Siegel, Orly Lipsitz et al. 59 citations

The majority of antidepressant medication trials have focused on adult populations (ages 18-65), with much less research in older and younger populations. Moreover, key differences in the efficacy and safety of antidepressants have been identified between these age groups. Ketamine has emerged as a promising new treatment for treatment resistant depression (TRD). The objective of this review is...

DOI: 10.1016/j.jpsychires.2021.02.058

Mindfulness intervention for mild cognitive impairment led to attention-related improvements and neuroplastic changes: Results from a 9-month randomized control trial.

Journal of Psychiatric Research March 1, 2021 Junhong Yu, Iris Rawtaer, Lei Feng et al.

Mindfulness-based interventions can enhance cognitive abilities among older adults, thereby effectively delaying cognitive decline. These cognitive enhancements are theorized to accompany neuroplastic changes in the brain. However, this mindfulness-associated neuroplasticity has yet to be documented adequately. A randomized controlled trial was carried out among participants with mild cognitive...

DOI: 10.1016/j.jpsychires.2021.01.032 Full text Meditation Mindfulness Neuroplasticity Attention +4

The efficacy of meditation-based mind-body interventions for mental disorders: A meta-review of 17 meta-analyses of randomized controlled trials.

Journal of Psychiatric Research February 1, 2021 Davy Vancampfort, Brendon Stubbs, Tine Van Damme et al.

There is increasing interest in the potential efficacy of meditation-based mind-body interventions (MBIs) within mental health care. We conducted a systematic metareview of the published randomized control trial (RCT) evidence. MEDLINE/PubMed, PsycARTICLES and EMBASE were searched from inception to 06/2020 examining MBIs (mindfulness, qigong, tai chi, yoga) as add-on or monotherapy versus no...

DOI: 10.1016/j.jpsychires.2020.12.048 Full text Depression Mindfulness ADHD Qigong +3

The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis.

Journal of Psychiatric Research December 11, 2020 Jiaqi Xiong, Orly Lipsitz, David C J Chen-Li et al. 122 citations

The efficacy of ketamine in reducing suicidal ideation (SI) has been previously reported. We aimed to evaluate acute anti-SI effects of single-dose ketamine in different formulations/routes of administration by pooling results from randomized controlled trials (RCTs). A systematic search was conducted on Cochrane, Embase, Medline, and PubMed from inception to July 1st, 2020. Studies were...

DOI: 10.1016/j.jpsychires.2020.12.038

Effects of mindfulness-based stress reduction on psychological distress in health workers: A three-arm parallel randomized controlled trial.

Journal of Psychiatric Research November 1, 2020 A. Errázuriz, K. Schmidt, E. Undurraga et al.

Mindfulness-based Stress Reduction (MBSR) has shown good efficacy for improving wellbeing in employees experiencing occupational stress. However, comparisons with other interventions, longer-term follow-up, and data from varying sociocultural contexts are lacking. This three-arm, parallel randomised controlled trial (RCT) examined the effects of MBSR on psychological distress in non-physician...

DOI: 10.1016/j.jpsychires.2020.11.011

The positive allosteric modulator of the mGlu2 receptor JNJ-46356479 partially improves neuropathological deficits and schizophrenia-like behaviors in a postnatal ketamine mice model.

Journal of Psychiatric Research April 26, 2020 Albert Martínez-pinteño, Susana García-Cerro, S. Mas et al.

Current antipsychotics have limited efficacy in controlling cognitive and negative symptoms of schizophrenia (SZ). Glutamatergic dysregulation has been implicated in the pathophysiology of SZ, based on the capacity of N-methyl-D-aspartate receptor (NMDAR) antagonists such as ketamine (KET) to induce SZ-like behaviors. This could be related to their putative neuropathological effect on...

DOI: 10.1016/j.jpsychires.2020.04.005

Ketamine in electroconvulsive therapy for depressive disorder: A systematic review and meta-analysis.

Journal of Psychiatric Research September 1, 2018 Li Ren, Jie Deng, S. Min et al. 48 citations

Electroconvulsive therapy (ECT) is one of the most effective treatments for depressive disorder. Sub-anesthetic dose of ketamine exerts a rapid and robust antidepressive effect. However, it is still unclear whether ketamine usage in ECT is efficacious as an antidepressant. We aimed to conduct a systematic review and meta-analysis on the effects of ketamine in ECT among patients with depressive...

DOI: 10.1016/j.jpsychires.2018.07.003

Kynurenine pathway metabolism and the neurobiology of treatment-resistant depression: Comparison of multiple ketamine infusions and electroconvulsive therapy.

Journal of Psychiatric Research February 10, 2018 Andrew P. Allen, Maura Naughton, J. Dowling et al. 53 citations

Current first-line antidepressants can take weeks or months to decrease depressive symptoms. Low dose ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, shows potential for a more rapid antidepressant effect, with efficacy also evident in previously treatment-resistant populations. However, a greater understanding of the physiological mechanisms underlying such effects is required....

DOI: 10.1016/j.jpsychires.2018.02.011 Full text

Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia

Journal of Psychiatric Research December 24, 2014 Ke Xu, John H. Krystal, Y. Ning et al. 65 citations

Objective Studies of the effects of the N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, ketamine, have suggested similarities to the symptoms of schizophrenia. Our primary goal was to evaluate the dimensions of the Positive and Negative Syndrome Scale (PANSS) in ketamine users (acute and chronic) compared to schizophrenia patients (early and chronic stages). Method We conducted...

DOI: 10.1016/j.jpsychires.2014.12.012 Full text

Papers